miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B–cell lymphoma

Zajdel, Michalina; Rymkiewicz, Grzegorz; Chechlińska, Magdalena; Błachnio, Katarzyna; Pieńkowska-Grela, Barbara; Grygalewicz, Beata; Goryca, Krzysztof; Cieslikowska, Maria; Bystydzieński, Zbigniew; Swoboda, Paweł; Walewski, Jan; Siwicki, Jan Konrad

doi:10.1007/s13277-015-3203-y

Cited by 18 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To evaluate cytomorphology of lymphoma cells, cytological smears from fine needle aspiration biopsy were used similarly as in histopathological examination. 4 Immunohistochemistry and FISH for the Epstein-Barr virus-encoded small RNA (EBER) were performed on formalin-fixed, paraffin-embedded tissues, as described by Zajdel et al 4…”

Section: Morphological and Immunohistochemical Characterizationmentioning

confidence: 99%

“…3 Remarkably, gene expression analyses of mRNA and miRNA showed major similarities in transcriptional profiles to MYC-positive Burkitt lymphoma. 2,4 Consequently, in the updated 2016 WHO classification, these lymphomas were recognized as a provisional entity MYC-negative 'Burkittlike lymphoma with 11q aberration'. 5 MYC-positive Burkitt lymphoma has typical histopathological and immunohistochemical features (CD20+/CD10+/BCL6+/BCL2 − /MUM1 − /MYC+/CD44 − /CD43+/Ki-67495%) in most cases, enabling differentiation from other, more common aggressive B-cell lymphomas.…”

mentioning

confidence: 99%

“…[6][7][8] Recently, lack of LMO2 expression by immunohistochemistry was found to be significantly associated with MYC translocations in CD10(+) aggressive B-cell lymphomas, including MYC-positive Burkitt lymphoma, 9 which is consistent with gene expression profiling studies, that have shown low levels of LMO2 gene expression in MYC-positive Burkitt lymphoma. 8 Rare Burkitt-like lymphoma with 11q aberration have recently been characterized with the use of immunohistochemistry, [1][2][3][4] but a detailed flow cytometry analysis of these cases compared to MYC-positive Burkitt lymphoma is missing.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration

et al. 2018

Self Cite

View full text Add to dashboard Cite

We previously described a subset of MYC translocation-negative aggressive B-cell lymphomas resembling Burkitt lymphoma, characterized by proximal gains and distal losses in chromosome 11. In the 2016 WHO classification, these MYC-negative lymphomas were recognized as a new provisional entity, 'Burkitt-like lymphoma with 11q aberration'. Here we present an immunophenotype analysis of Burkitt-like lymphomas with 11q aberration. Cells were acquired by fine needle aspiration biopsy from 10 young adult patients, 80% of whom presented recurrence-free 5-year survival. Twenty-three MYC-positive Burkitt lymphomas, including three carrying both MYC rearrangement and 11q aberration, served as controls. By immunohistochemistry, all Burkitt-like lymphomas with 11q aberration were CD20+/CD10+/BCL6+/BCL2-/MUM1-/MYC+/EBV-, usually LMO2+/CD44-/CD43- and sometimes CD56+, and showed high proliferation rate. By flow cytometry, Burkitt-like lymphoma with 11q aberration immunophenotypically resembled MYC-positive Burkitt lymphoma, except for significantly (adjusted P<0.001) more frequent CD38 expression in Burkitt lymphoma (91% MYC-positive Burkitt lymphoma vs 10% Burkitt-like lymphoma with 11q aberration), more frequently diminished CD45 expression in Burkitt lymphoma (74% vs 10%), an exclusive CD16/CD56 and highly restricted CD8 expression in Burkitt-like lymphoma with 11q aberration (60% vs 0% and 40% vs 4%, respectively). We showed high diagnostic accuracy and effectiveness of flow cytometry in Burkitt lymphoma. CD16/CD56 expression without CD38 and the lack of CD16/CD56 with CD38 expression proves to be a reliable, fast, and cost-effective method for diagnosing 11q aberration and MYC rearrangements in CD10(+) aggressive lymphomas, respectively. In addition, we confirmed a pattern of an inverted duplication with telomeric loss of 11q, as a recurrent 11q abnormality, but one case presented alternative changes, possibly resulting in an equivalent molecular effect. Our findings reveal similarities along with subtle but essential differences in the immunophenotype of Burkitt-like lymphoma with 11q aberration and MYC-positive Burkitt lymphoma, important for the differential diagnosis, but also for understanding the pathogenesis of Burkitt-like lymphoma with 11q aberration.

show abstract

Section: Morphological and Immunohistochemical Characterizationmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…5). MYC-negative BLL,11q shows a number of clinico-pathological similarities to MYC-positive BL, but also harbour some significant differences in immunoprofile [1,45,46,47,48,49,50]. BLL,11q usually express CD43/LMO2/CD56 in IHC and CD16/CD56/CD38/CD45/CD8/CD43 in FCM.…”

Section: Burkitt Lymphoma and Burkitt-like Lymphoma With 11q Aberrationmentioning

confidence: 99%

Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation’s 2017 classification

Szumera‐Ciećkiewicz¹,

Rymkiewicz²,

Grygalewicz³

et al. 2018

pjp

Self Cite

View full text Add to dashboard Cite

Revision of the fourth edition of the World Health Organisation (WHO) Classification of Haematopoietic and Lymphatic Tissues, which was published in 2017, introduced important changes updating the biology, pathology, genetics, and clinical presentation of aggressive B-cell lymphomas. High grade B-cell lymphomas (HG-BLs) replaced B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, the new provisional entityBurkitt-like lymphoma with 11q aberration was identified, and some categories were upgraded, e.g. EBV-positive diffuse large B-cell lymphoma, not otherwise specified. Still the histopathological diagnostics is based on morphology and immunoprofile, but to define the HGBLs evaluation of MYC, BCL2, and BCL6 gene statuses is required. According to the presented WHO criteria, in the comprehensive histopathological diagnostics of aggressive B-cell lymphomas a highly specialised diagnostic team including a pathologist, a molecular biologist, a geneticist, a haematologist, and immunophenotyping technicians is needed.

show abstract

“…Recently, a subgroup of germinal center-derived B-cell (GCB) lymphomas has been described that resembles Burkitt lymphoma (BL) with regard to morphology, immunophenotype, and gene-expression profile but it lacks the IG-MYC translocation typical for BL. [1][2][3][4][5] Instead, these cases are cytogenetically characterized by a peculiar pattern of an 11q aberration consisting of a gain in 11q23.2-23.3 followed by a telomeric loss in 11q24.1-qter. According to the revised 4th edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, these lymphomas have been described as a new provisional entity called "Burkitt-like lymphoma with 11q aberration" (abbreviated herein as "mnBLL,11q,").…”

Section: Introductionmentioning

confidence: 99%

The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma

Wagener

Seufert

Raimondi³

et al. 2019

Blood

Self Cite

View full text Add to dashboard Cite

The new recently described provisional lymphoma category Burkitt-like lymphoma with 11q aberration comprises cases similar to Burkitt lymphoma (BL) on morphological, immunophenotypic and gene-expression levels but lacking the IG-MYC translocation. They are characterized by a peculiar imbalance pattern on chromosome 11, but the landscape of mutations is not yet described. Thus, we investigated 15 MYC-negative Burkitt-like lymphoma with 11q aberration (mnBLL,11q,) cases by copy-number analysis and whole-exome sequencing. We refined the regions of 11q imbalance and identified the INO80 complex-associated gene NFRKB as a positional candidate in 11q24.3. Next to recurrent gains in 12q13.11-q24.32 and 7q34-qter as well as losses in 13q32.3-q34, we identified 47 genes recurrently affected by protein-changing mutations (each ≥3 of 15 cases). Strikingly, we did not detect recurrent mutations in genes of the ID3-TCF3 axis or the SWI/SNF complex that are frequently altered in BL, or in genes frequently mutated in germinal center–derived B-cell lymphomas like KMT2D or CREBBP. An exception is GNA13, which was mutated in 7 of 15 cases. We conclude that the genomic landscape of mnBLL,11q, differs from that of BL both at the chromosomal and mutational levels. Our findings implicate that mnBLL,11q, is a lymphoma category distinct from BL at the molecular level.

show abstract

miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B–cell lymphoma

Cited by 18 publications

References 39 publications

A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration

A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration

Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation’s 2017 classification

The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma

Contact Info

Product

Resources

About